Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

494 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
Shoji H, Yoshio S, Mano Y, Doi H, Sugiyama M, Osawa Y, Kimura K, Arai T, Itokawa N, Atsukawa M, Aoki Y, Fukai M, Taketomi A, Mizokami M, Kanto T. Shoji H, et al. Among authors: Osawa Y. Int J Cancer. 2017 Sep 1;141(5):1011-1017. doi: 10.1002/ijc.30804. Epub 2017 Jun 8. Int J Cancer. 2017. PMID: 28555943 Clinical Trial.
Liver disease secondary to congenital heart disease in children.
Komatsu H, Inui A, Kishiki K, Kawai H, Yoshio S, Osawa Y, Kanto T, Fujisawa T. Komatsu H, et al. Among authors: Osawa Y. Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):651-666. doi: 10.1080/17474124.2019.1621746. Epub 2019 May 26. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31131680 Review.
Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers.
Osawa Y, Kojika E, Nishikawa K, Kimura M, Osakaya S, Miyauchi H, Kanto T, Kawakami Y, Kimura K. Osawa Y, et al. Oncotarget. 2019 Apr 30;10(32):3013-3026. doi: 10.18632/oncotarget.26892. eCollection 2019 Apr 30. Oncotarget. 2019. PMID: 31105882 Free PMC article.
Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.
Kimura K, Ikoma A, Shibakawa M, Shimoda S, Harada K, Saio M, Imamura J, Osawa Y, Kimura M, Nishikawa K, Okusaka T, Morita S, Inoue K, Kanto T, Todaka K, Nakanishi Y, Kohara M, Mizokami M. Kimura K, et al. Among authors: Osawa Y. EBioMedicine. 2017 Sep;23:79-87. doi: 10.1016/j.ebiom.2017.08.016. Epub 2017 Aug 19. EBioMedicine. 2017. PMID: 28844410 Free PMC article. Clinical Trial.
Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis in Mice.
Osawa Y, Oboki K, Imamura J, Kojika E, Hayashi Y, Hishima T, Saibara T, Shibasaki F, Kohara M, Kimura K. Osawa Y, et al. EBioMedicine. 2015 Oct 8;2(11):1751-8. doi: 10.1016/j.ebiom.2015.10.010. eCollection 2015 Nov. EBioMedicine. 2015. PMID: 26870800 Free PMC article.
Selective inhibitor of Wnt/β-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model.
Tokunaga Y, Osawa Y, Ohtsuki T, Hayashi Y, Yamaji K, Yamane D, Hara M, Munekata K, Tsukiyama-Kohara K, Hishima T, Kojima S, Kimura K, Kohara M. Tokunaga Y, et al. Among authors: Osawa Y. Sci Rep. 2017 Mar 23;7(1):325. doi: 10.1038/s41598-017-00282-w. Sci Rep. 2017. PMID: 28336942 Free PMC article.
Liver acid sphingomyelinase inhibits growth of metastatic colon cancer.
Osawa Y, Suetsugu A, Matsushima-Nishiwaki R, Yasuda I, Saibara T, Moriwaki H, Seishima M, Kozawa O. Osawa Y, et al. J Clin Invest. 2013 Feb;123(2):834-43. doi: 10.1172/JCI65188. Epub 2013 Jan 9. J Clin Invest. 2013. PMID: 23298833 Free PMC article.
494 results
Jump to page
Feedback